Cramer's week ahead: Earnings from JPMorgan, Netflix, Goldman Sachs and PepsiCo
"Once we process the new tariffs, we've got a ton of earnings reports coming next week, so you better keep your eyes open," he said.
Tuesday brings earnings from financial giants JPMorgan, Wells Fargo, Citigroup and BlackRock, and Cramer said he'll be waiting to hear whether there has been any slowdown in spending or pick up in loan losses. While he said JPMorgan is "the star of the show," he also cares about Wells Fargo, which is no longer subject to a punitive asset cap. Cramer predicted Citigroup's report would be well-received, but he said BlackRock might tell "the most exciting story." The Labor Department will release the consumer price index report on Tuesday, Cramer added, an important metric for the Federal Reserve when it makes decisions about interest rates.
On Wednesday, Goldman Sachs and Morgan Stanley are set to report, and Cramer said he's optimistic both outfits will post strong quarters as mergers and acquisitions heat up. He said there could be "another round of semi buying" if semiconductor capital equipment company ASML releases a solid report. Bank of America and Johnson & Johnson will report on Wednesday as well. Cramer said Bank of America has put up consistently good earnings and suggested the stock was cheap because Berkshire Hathaway has been selling shares. Cramer said the pharmaceutical giant still has litigation hanging over its head.
Retail sales figures will come out Thursday, and Cramer said he's worried about a slowdown as political chaos affects consumers. Abbott Laboratories, PepsiCo and Netflix are set to report Thursday. Cramer said Abbott's quarter tends to be "misinterpreted in a negative way," saying the healthcare name is one of his favorite companies. Cramer called PepsiCo "too cheap relative to its growth rate," and he noted different factors that could be weighing on the stock, like the rise of GLP-1 weight loss drugs and scrutiny on junk food from Health and Human Services Secretary Robert F. Kennedy Jr. Cramer said he bets Netflix will report a great quarter, but he said the bar for the streaming giant is high.
On Friday, American Express, 3M and Charles Schwab will report earnings. According to Cramer, American Express tends to sell off even when the report is good. The industrial sector has been doing well lately, and Cramer said 3M might report one of the best quarters of the group. He was also optimistic about Charles Schwab, but said "the short-sellers like to come out and color the opening of trading when Schwab opens," advising investors to be careful before they buy.
Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter.Disclaimer The CNBC Investing Club Charitable Trust owns shares of Wells Fargo, BlackRock, Goldman Sachs and Abbott Laboratories.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
39 minutes ago
- Bloomberg
JPMorgan Says Korean Stock Gauge May Near 5,000 Over Two Years
South Korea's equity benchmark may rise more than 50% from its current level over a two-year period should corporate governance reforms gain momentum, according to JPMorgan Chase & Co. Korea remains a key overweight market in Asia and among emerging markets, strategists led by Mixo Das wrote in a note on Friday. The Kospi Index, which has gained 32% so far this year to near a record high, could reach around 5,000, they said. That compares with Friday's close of around 3,176.
Yahoo
an hour ago
- Yahoo
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, 2025, marking a significant progress in the treatment of relapsed or refractory multiple myeloma in patients who have undergone four or more prior therapies. The approval adds depth to the company's late-stage pipeline. Moreover, it enhances the company's long-term growth trajectory in a high-need, underserved segment of the cancer market. A medical professional holding vials of biotechnology therapeutic candidate. On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 price target. Although Regeneron has faced recent headwinds, particularly around Eylea, Schott expects those pressures to ease. He points to patient affordability issues and competitive dynamics as near-term hurdles, but believes the enhanced Eylea HD formulation and expanded copay assistance programs should help stabilize sales. Offsetting some of this softness is the continued strength of Dupixent, which Schott sees as a key growth engine, especially as new indications expand its market reach. Looking ahead, Schott views the setup for Regeneron shares as compelling. With a strong balance sheet and growing contributions from Dupixent, he sees room for upside even without relying on near-term pipeline catalysts. However, potential updates, including LAG-3 data in melanoma and further clarity on Eylea, could serve as meaningful valuation drivers. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is a biotechnology company focused on discovering, developing, and distributing innovative therapies that address serious and life-threatening diseases. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
Top Analysts Raise the Bar on Netflix Stock (NFLX) Ahead of Q2 Earnings
Netflix (NFLX) is back in the spotlight as several top analysts lift their price targets ahead of the company's highly anticipated Q2 earnings report, scheduled for July 17. Growing optimism around subscriber growth, ad-tier performance, and margin expansion is making Wall Street increasingly bullish on the streaming giant's outlook. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Overall, analysts expect Netflix to report an EPS (earnings per share) of $7.07 for Q2, up from $4.88 in the same quarter last year. Meanwhile, analysts project Q2 revenues at $11.4 billion, according to the TipRanks Analyst Forecasts Page. Let's look at the recent ratings on NFLX stock. KeyBanc's five-star-rated analyst Justin Patterson raised his price target on NFLX stock from $1,070 to $1,390 while keeping his Buy rating. Patterson remains upbeat on Netflix, citing strong revenue growth potential over the next few years. He expects low double-digit revenue growth driven by rising ad sales, price hikes, and new live content. While he acknowledges some near-term volatility, especially as hit series like Wednesday and Stranger Things wrap up, he believes Netflix's ability to deliver surprise content hits and expand into live programming will keep users engaged and support long-term growth. Overall, KeyBanc estimates Netflix could earn nearly $40 in EPS by 2027, backing its new $1,390 price target based on a 35x multiple of those projected earnings. Needham Lifts Netflix Target on Solid Productivity Gains Needham analyst Laura Martin raised Netflix's price target to $1,500 from $1,126, highlighting the company's strong employee productivity. Netflix leads nine large-cap firms (tracked by Needham) in revenue per employee with nearly double the group average, underscoring efficient workforce performance. Needham sees this as a key driver of long-term financial returns. Additionally, the firm connected Netflix's employee quality and culture to its strong financial performance, saying metrics like returns per employee help measure whether a company hires top-tier, value-generating talent. Is Netflix a Good Long-Term Investment? Turning to Wall Street, NFLX stock carries a Moderate Buy consensus rating. Among the 38 analysts covering the stock, 28 have issued Buy recommendations, and 10 rate it as Hold. Moreover, the average Netflix stock price target of $1,297.38 implies a 3.74% upside potential from current levels. Year-to-date, NFLX stock has gained 40%.
